
Avita Medical, Inc.: updates and filings
Price
$16.83
November 18, 2026Market cap $516M
What Ploutos Investor adds for Avita Medical
Part of Ploutos Investor, €9.99 a month
- The full history: 9 fiscal years, from FY2017
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Regulation FD disclosureForm8-K
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Nov 2, 2026Regulation FD disclosureForm8-K
- Aug 25, 2026Shares registered for employeesFormS-8
- Aug 11, 2026Material agreement enteredForm8-K
- Aug 6, 2026Shareholder vote (amendment)Form8-K/A
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jun 8, 2026Material agreement enteredForm8-K
- Jun 4, 2026Officer or director change, shareholder voteForm8-K
- May 14, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 14, 2026Results of operationsForm8-K
- May 1, 2026Officer or director change, Regulation FD disclosureForm8-K
- Apr 22, 2026Annual meeting proxy statementFormDEF 14A
- Apr 9, 2026FilingFormEFFECT
- Apr 8, 2026Preliminary proxy statementFormPRE 14A
- Apr 7, 2026Correspondence with the SECFormCORRESP
- Apr 6, 2026Letter from the SECFormUPLOAD
- Mar 31, 2026Shelf registration for future offeringsFormS-3
- Feb 12, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 12, 2026Results of operationsForm8-K
- Jan 30, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jan 13, 2026Material agreement entered, material agreement ended, results of operations, new material financial obligation, unregistered sale of sharesForm8-K
- Jan 5, 2026Officer or director changeForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Nov 2, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 25, 2026 | S-8 | Shares registered for employees | Document |
| Aug 11, 2026 | 8-K | Material agreement entered | Document |
| Aug 6, 2026 | 8-K/A | Shareholder vote (amendment) | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jun 8, 2026 | 8-K | Material agreement entered | Document |
| Jun 4, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 14, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 14, 2026 | 8-K | Results of operations | Document |
| May 1, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Apr 22, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 9, 2026 | EFFECT | Filing | Document |
| Apr 8, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Apr 7, 2026 | CORRESP | Correspondence with the SEC | Document |
| Apr 6, 2026 | UPLOAD | Letter from the SEC | Document |
| Mar 31, 2026 | S-3 | Shelf registration for future offerings | Document |
| Feb 12, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 12, 2026 | 8-K | Results of operations | Document |
| Jan 30, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jan 13, 2026 | 8-K | Material agreement entered, material agreement ended, results of operations, new material financial obligation, unregistered sale of shares | Document |
| Jan 5, 2026 | 8-K | Officer or director change | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 19, 2018.
The full analysis
What do Avita Medical's filings show?
The filings are where every one of Avita Medical's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.